BNP Paribas Financial Markets
TLIS

BNP Paribas Financial Markets’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

BNP Paribas Financial Markets’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37
Closed -$382 – 4746
2022
Q3 		$382 Buy
+37
New +$468 ﹤0.01% 4550

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

BNP Paribas Financial Markets's TLIS Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2022, closing a stake of 37 shares — an estimated $382 sold.

BNP Paribas Financial Markets first reported a position in TLIS in Q3 2022 and held it in 1 quarter. The position peaked at $382 in Q3 2022. 27 funds tracked by Wall St. Rank hold TLIS as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 37 Talis Biomedical Corporation Common Stock shares in Q4 2022, an estimated $382.
  • BNP Paribas Financial Markets first reported a position in Talis Biomedical Corporation Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Talis Biomedical Corporation Common Stock position peaked at $382 in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.